IL111601A0 - Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna - Google Patents

Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna

Info

Publication number
IL111601A0
IL111601A0 IL11160194A IL11160194A IL111601A0 IL 111601 A0 IL111601 A0 IL 111601A0 IL 11160194 A IL11160194 A IL 11160194A IL 11160194 A IL11160194 A IL 11160194A IL 111601 A0 IL111601 A0 IL 111601A0
Authority
IL
Israel
Prior art keywords
dna
rna
conjugate
vector
encoding
Prior art date
Application number
IL11160194A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL111601A0 publication Critical patent/IL111601A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IL11160194A 1993-11-12 1994-11-11 Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna IL111601A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy

Publications (1)

Publication Number Publication Date
IL111601A0 true IL111601A0 (en) 1995-01-24

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11160194A IL111601A0 (en) 1993-11-12 1994-11-11 Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna

Country Status (15)

Country Link
US (2) US6140100A (it)
EP (1) EP0728018B1 (it)
JP (1) JPH09507834A (it)
AT (1) ATE246516T1 (it)
AU (1) AU688412B2 (it)
CA (1) CA2176024A1 (it)
DE (1) DE69433015T2 (it)
DK (1) DK0728018T3 (it)
ES (1) ES2204935T3 (it)
GB (1) GB9323429D0 (it)
IL (1) IL111601A0 (it)
MY (1) MY114140A (it)
NZ (1) NZ276137A (it)
WO (1) WO1995013095A2 (it)
ZA (1) ZA948987B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
CN1095677C (zh) * 1994-12-23 2002-12-11 曾尼卡有限公司 化合物
CN1193278A (zh) * 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
AU2205499A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
CA2390650A1 (en) 1999-11-12 2001-05-17 Lexicon Genetics Incorporated Novel human proteases and polynucleotides encoding the same
EP1343531A2 (en) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Conjugates of antibodies and anticancer drugs
SI1425001T1 (sl) 2001-09-14 2009-04-30 Glaxo Group Ltd Glaxo Welcome Fenetanolaminski derivati za zdravljenje respiratornih bolezni
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
EP1725250A2 (en) * 2004-02-18 2006-11-29 Frutarom Ltd. Method for the preparation of peptide-oligonucleotide conjugates
WO2006035008A1 (de) * 2004-09-27 2006-04-06 Merck Biosciences Ag Rekombinante carboxypeptidase b
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP2491788B1 (en) 2011-02-25 2015-12-23 Kraft Foods R & D, Inc. Food product with a moulded body
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
SG11201604993WA (en) * 2013-12-17 2016-07-28 Stella Pharma Corp A method for producing 2-fluoro-4-borono-l-phenylalanine, and precursor of 2-fluoro-4-borono-l-phenylalanine
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
WO2022272307A1 (en) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
WO1990007929A1 (en) * 1989-01-23 1990-07-26 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
MY114140A (en) 2002-08-30
ZA948987B (en) 1996-05-13
AU688412B2 (en) 1998-03-12
US6319702B1 (en) 2001-11-20
EP0728018A1 (en) 1996-08-28
CA2176024A1 (en) 1995-05-18
DE69433015T2 (de) 2004-06-09
US6140100A (en) 2000-10-31
AU8148894A (en) 1995-05-29
GB9323429D0 (en) 1994-01-05
ATE246516T1 (de) 2003-08-15
EP0728018B1 (en) 2003-08-06
NZ276137A (en) 1998-04-27
DK0728018T3 (da) 2003-11-24
JPH09507834A (ja) 1997-08-12
DE69433015D1 (de) 2003-09-11
WO1995013095A3 (en) 1995-07-13
WO1995013095A2 (en) 1995-05-18
ES2204935T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
IL111601A0 (en) Conjugate comprising a targetting molecule, dna or rna encoding it, vector and cell ling containing said dna or rna
CA2205382A1 (en) Enzymatic dna molecules
AU4526193A (en) Binding competent oligomers containing 2', 5' linkages
AU1430097A (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2000003685A3 (en) Nitrilase homologs
MXPA03002413A (es) Moleculas tipo b7 y uso de las mismas.
IL123667A0 (en) Pneumococcal genes portions thereof expression products therefrom and uses of such genes portions and products
AU2434195A (en) Thymidine kinase mutants
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE
WO2000053776A3 (en) Human kallikrein-like genes
HUT75717A (en) Nucleic acid molecules encoding cytoplasmatic alcohol dehydrogenase and glutamil-cystein synthetase, vectors to introduce them and processes employing these vectors
AUPP472398A0 (en) Protease susceptibility II
AU6724794A (en) GRB3-3 gene, its variants and their uses
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
ZA97835B (en) Purified sr-p70 protein
EP0643719A4 (en) NUCLEIC ACID SEQUENCES ENCODING NUCLEIC ACID SEQUENCES ENCODING THE INTERLEUKIN-9 RECEPTOR, OR COMPLEMENTARY TO THESE SEQUENCES.
WO1996015240A3 (en) Ribozyme analogs
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof
AU782261C (en) Novel glycosyltransferase genes
MXPA01004353A (es) Antigenos de chlamydia y los correspondientes fragmentos de adn y usos de los mismos.
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
ZA961419B (en) Human DNase I variants.
WO2000040607A3 (en) Tiam2 (t-cell lymphoma invasion and metastasis 2) nucleotide exchange factor